Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Curran, D.
Right arrow Articles by Giaccone, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Curran, D.
Right arrow Articles by Giaccone, G.

Journal of Clinical Oncology, Vol 16, 145-152, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

D Curran, T Sahmoud, P Therasse, J van Meerbeeck, PE Postmus and G Giaccone
European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium.

PURPOSE: Identification of prognostic factors in patients with malignant pleural mesothelioma based on prospectively collected international data. PATIENTS AND METHODS: From October 1984 to October 1993, 204 eligible adult patients with malignant pleural mesothelioma were entered into five consecutive prospective European Organization for Research and Treatment of Cancer (EORTC) phase II clinical trials designed to assess the efficacy of various anticancer drugs (mitoxantrone, epidoxorubicin, etoposide, and paclitaxel). The Cox model was used to assess 13 factors related to biology and disease history with respect to survival. RESULTS: The median survival duration was 12.6 months from diagnosis and 8.4 months from trial entry. In the multivariate analysis, poor prognosis was associated with a poor performance status, a high WBC count, a probable/possible histologic diagnosis of mesothelioma, male gender, and having sarcomatous tissue as the histologic subtype. Taking these five factors into consideration, patients were classified into two groups: a good- prognosis group (1-year survival rate, 40%; 95% confidence interval [CI], 30% to 50%) and a poor-prognosis group (1-year survival, 12%; 95% CI, 4% to 20%). CONCLUSION: These results may help to design new clinical trials in pleural mesothelioma by selecting more homogenous groups of patients.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. G. Tournoy, S. A. Burgers, J. T. Annema, F. Vermassen, M. Praet, M. Smits, H. M. Klomp, J. P. van Meerbeeck, and P. Baas
Transesophageal Endoscopic Ultrasound with Fine Needle Aspiration in the Preoperative Staging of Malignant Pleural Mesothelioma
Clin. Cancer Res., October 1, 2008; 14(19): 6259 - 6263.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A Chapman, S Mulrennan, B Ladd, and M F Muers
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
Thorax, May 1, 2008; 63(5): 435 - 439.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Janne, G. R. Simon, C. J. Langer, R. N. Taub, A. Dowlati, P. Fidias, M. Monberg, C. Obasaju, and H. Kindler
Phase II Trial of Pemetrexed and Gemcitabine in Chemotherapy-Naive Malignant Pleural Mesothelioma
J. Clin. Oncol., March 20, 2008; 26(9): 1465 - 1471.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
D. Nguyen, S.-J. Lee, E. Libby, and C. Verschraegen
Rate of Thromboembolic Events in Mesothelioma
Ann. Thorac. Surg., March 1, 2008; 85(3): 1032 - 1038.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
P. Borasio, A. Berruti, A. Bille, P. Lausi, M. G. Levra, R. Giardino, and F. Ardissone
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients
Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 307 - 313.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bottomley, C. Coens, F. Efficace, R. Gaafar, C. Manegold, S. Burgers, M. Vincent, C. Legrand, and J. P. van Meerbeeck
Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma
J. Clin. Oncol., December 20, 2007; 25(36): 5770 - 5776.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W Weder, R. Stahel, J Bernhard, S Bodis, P Vogt, P Ballabeni, D Lardinois, D Betticher, R Schmid, R Stupp, et al.
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
Ann. Onc., July 1, 2007; 18(7): 1196 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. L. Ceresoli, C. Gridelli, and A. Santoro
Multidisciplinary Treatment of Malignant Pleural Mesothelioma
Oncologist, July 1, 2007; 12(7): 850 - 863.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
J. G. Edwards, A. E. Martin-Ucar, D. J. Stewart, and D. A. Waller
Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy?: Short- and long-term results
Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 759 - 764.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
P. S. Adusumilli, M.-K. Chan, M. Hezel, Z. Yu, B. M. Stiles, T.-C. Chou, V. W. Rusch, and Y. Fong
Radiation-Induced Cellular DNA Damage Repair Response Enhances Viral Gene Therapy Efficacy in the Treatment of Malignant Pleural Mesothelioma
Ann. Surg. Oncol., January 1, 2007; 14(1): 258 - 269.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. L. Ceresoli, A. Chiti, P. A. Zucali, M. Rodari, R. F. Lutman, S. Salamina, M. Incarbone, M. Alloisio, and A. Santoro
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
J. Clin. Oncol., October 1, 2006; 24(28): 4587 - 4593.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
A Scattone, A Pennella, M Gentile, M Musti, P Nazzaro, A L Buonadonna, A Marzullo, D Cavone, L Pollice, and G Serio
Comparative genomic hybridisation in malignant deciduoid mesothelioma
J. Clin. Pathol., July 1, 2006; 59(7): 764 - 769.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. L. Ceresoli, P. A. Zucali, A. G. Favaretto, F. Grossi, P. Bidoli, G. Del Conte, A. Ceribelli, A. Bearz, E. Morenghi, R. Cavina, et al.
Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma
J. Clin. Oncol., March 20, 2006; 24(9): 1443 - 1448.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bottomley, R. Gaafa, C. Manegold, S. Burgers, C. Coens, C. Legrand, M. Vincent, G. Giaccone, and J. Van Meerbeeck
Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study
J. Clin. Oncol., March 20, 2006; 24(9): 1435 - 1442.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. Deraco, D. Nonaka, D. Baratti, P. Casali, J. Rosai, R. Younan, A. Salvatore, A. D. Cabras, and S. Kusamura
Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
Ann. Surg. Oncol., February 1, 2006; 13(2): 229 - 237.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. E. R. O'Brien, D. Watkins, C. Ryan, K. Priest, C. Corbishley, A. Norton, S. Ashley, N. Rowell, and R. Sayer
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial
Ann. Onc., February 1, 2006; 17(2): 270 - 275.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. van Meerbeeck, R. Gaafar, C. Manegold, R. J. Van Klaveren, E. A. Van Marck, M. Vincent, C. Legrand, A. Bottomley, C. Debruyne, and G. Giaccone
Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
J. Clin. Oncol., October 1, 2005; 23(28): 6881 - 6889.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. Anton and M. Pistolesi
Malignant Pleural Mesothelioma With Less-Frequent Features
Chest, August 1, 2005; 128(2): 1068 - 1068.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J. P. C. Steele and A. Klabatsa
Chemotherapy options and new advances in malignant pleural mesothelioma
Ann. Onc., March 1, 2005; 16(3): 345 - 351.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Fennell, A. Parmar, J. Shamash, M. T. Evans, M. T. Sheaff, R. Sylvester, K. Dhaliwal, N. Gower, J. Steele, and R. Rudd
Statistical Validation of the EORTC Prognostic Model for Malignant Pleural Mesothelioma Based on Three Consecutive Phase II Trials
J. Clin. Oncol., January 1, 2005; 23(1): 184 - 189.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Pistolesi and J. Rusthoven
Malignant Pleural Mesothelioma: Update, Current Management, and Newer Therapeutic Strategies
Chest, October 1, 2004; 126(4): 1318 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Weder, P. Kestenholz, C. Taverna, S. Bodis, D. Lardinois, M. Jerman, and R. A. Stahel
Neoadjuvant Chemotherapy Followed by Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma
J. Clin. Oncol., September 1, 2004; 22(17): 3451 - 3457.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Andreopoulou, P. J. Ross, M. E. R. O'Brien, H. E. R. Ford, K. Priest, T. Eisen, A. Norton, S. Ashley, and I. E. Smith
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma
Ann. Onc., September 1, 2004; 15(9): 1406 - 1412.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. Ebstein, C. Sapede, P.-J. Royer, M. Marcq, C. Ligeza-Poisson, I. Barbieux, L. Cellerin, G. Dabouis, and M. Gregoire
Cytotoxic T Cell Responses against Mesothelioma by Apoptotic Cell-pulsed Dendritic Cells
Am. J. Respir. Crit. Care Med., June 15, 2004; 169(12): 1322 - 1330.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. G. Edwards, D. E. B. Swinson, J. L. Jones, S. Muller, D. A. Waller, and K. J. O'Byrne
Tumor Necrosis Correlates With Angiogenesis and Is a Predictor of Poor Prognosis in Malignant Mesothelioma
Chest, November 1, 2003; 124(5): 1916 - 1923.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. H. Schouwink, L. Schultze Kool, E. J. Rutgers, F. A. N. Zoetmulder, N. van Zandwijk, M. J. v.d. Vijver, and P. Baas
The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma
Ann. Thorac. Surg., June 1, 2003; 75(6): 1715 - 1718.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
W. R. Smythe, I. Mohuiddin, M. Ozveran, and X. X. Cao
Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product
J. Thorac. Cardiovasc. Surg., June 1, 2002; 123(6): 1191 - 1198.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
I. Monnet, J.-L. Breau, D. Moro, H. Lena, J.-C. Eymard, O. Menard, J.-P. Vuillez, M. Chokri, J.-L. Romet-Lemonne, and M. Lopez
Intrapleural Infusion of Activated Macrophages and {gamma}-Interferon in Malignant Pleural Mesothelioma* : A Phase II Study
Chest, June 1, 2002; 121(6): 1921 - 1927.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. G. Edwards, S. P. Faux, S. M. Plummer, K. R. Abrams, R. A. Walker, D. A. Waller, and K. J. O'Byrne
Cyclooxygenase-2 Expression Is a Novel Prognostic Factor in Malignant Mesothelioma
Clin. Cancer Res., June 1, 2002; 8(6): 1857 - 1862.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Mikulski, J. J. Costanzi, N. J. Vogelzang, S. McCachren, R. N. Taub, H. Chun, A. Mittelman, T. Panella, C. Puccio, R. Fine, et al.
Phase II Trial of a Single Weekly Intravenous Dose of Ranpirnase in Patients With Unresectable Malignant Mesothelioma
J. Clin. Oncol., January 1, 2002; 20(1): 274 - 281.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Pataer, W. R. Smythe, R. Yu, B. Fang, T. McDonnell, J. A. Roth, and S. G. Swisher
Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines
J. Thorac. Cardiovasc. Surg., January 1, 2001; 121(1): 0061 - 67.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J G Edwards, K R Abrams, J N Leverment, T J Spyt, D A Waller, and K J O'Byrne
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
Thorax, September 1, 2000; 55(9): 731 - 735.
[Abstract] [Full Text]

Home page
 ThoraxHome page
J P C STEELE and R M RUDD
Malignant mesothelioma: predictors of prognosis and clinical trials
Thorax, September 1, 2000; 55(9): 725a - 726.
[Full Text]

Home page
 The OncologistHome page
E. G. Butchart
Contemporary Management of Malignant Pleural Mesothelioma
Oncologist, December 1, 1999; 4(6): 488 - 500.
[Abstract] [Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1998 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online